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E lectrophoretic migration patterns of murine tyrosinases 
Authors Ref %1' Tissue T, T, 
B w-nett et al [10] 7.0 B-16 melanoma .61 .51 
Burnett et al [10] 7.0 Harding Passey melanoma .62 .52 
B urnett et al [10] 7.0 S-91 melanoma .62 .51 
Holstein et a l [11] 7.0 coat color mutants .69 .53 
Burnett et a l [1 2] 7.0 normal hair bulbs .70 .54 
Holstein et a l [13] 7.0 coat color mutants .70 .54 
Miyazaki & Seiji [14] 7.0 Harding Passey melanoma .63 
N ishioka et a l [7] 7.0 S-91 melanoma .65 .53 
.65 ± .04 .53 ± .01 
Hearing & Ekel [8] 7.5 S-91 melanoma .55 .44 
Eppig & Hearing [15] 7.5 normal epidermis .60 .46 
Eppig & Hearing [15] 7.5 S-91 melanoma .61 .46 
Klingler et a l [16] 7.5 B-16 melanoma .59 .50 
Klingler et a l [16] 7.5 S-91 melanoma .59 .50 
Wh ite & Hu [5] 7.5 B-16 melanoma .60 
H earing et al [6] 7.5 B-16 melanoma .56 .45 
.59 ± .02 .47 ± .03 
S h apiro et a l [1] 7.5 Harding-Passey melanoma .44 .30 
All figures are those given by the author (if none were given, actual gels were measured) . Most data represent the average of many such gels. 
1. The tyrosine level used in their assay (0.66 mM) has been shown 
to be inhib itory by several workers-the safest levels of tyrosine to use 
to avoid competitive inhibition is a full order of magnitude less 
[3, 8, 9]. 
2. More importantly, however, was the fac t that their enzyme prep-
aration most probably contained li ttle or no tyrosinase. In our earlier 
paper [8) which discussed the purification scheme employed by the 
Patel and Okun group, we showed tha t the technique modifications 
t h at they employed were less than adequate, since only about 0.2% of 
t h e tyrosinase activity was recovered, with a specific activity that was 
reduced, indicating no purification at all. S hapiro et al, employing those 
same methods for some reason, appear to have purified the same 
n o ntyrosinase proteins that we had shown by gel electrophoresis in our 
earLi er paper. A comparison of the impure preparations (cf their Fig 1, 
w ith more than 9 proteins) with the clean preparations of the original 
Burnett papers will suffice to prove this point. Further, a quick scan of 
t h e literature (Table 1) over the past 15 years on tyrosinases found in 
a variety of normal and malignant murine systems shows that the 
relative mobilit ies of the major isozyme (1',) on 7.5% acrylamide gels 
are around 0.59; on 7% ac rylamide gels, it moves even faster (R", 0.65). 
The 1'2 isozyme, which is a minor tyrosinase isozyme, is somewhat 
s lower . T he 2 bands purified by Shapiro et al had relative mobilities 
s ignificantly slower than that, 0.44 and 0.30, respectively. This is very 
close to the elec trophoretic da ta for DOPA-posit ive proteins that we 
obtained for the same preparation in our earlier paper (0.47 and 0.35) ; 
we have no idea what proteins these represent- they must be oxidizing 
in natw-e since we, as well as the Shapiro group, found that they were 
capable of oxidizing L· DOPA to melanin. It is feasib le that these bands 
represent hemoglobin, or a similar protein, which is capable of oxidizing 
L-DOPA; it should not be ignored that both Holstein et al [4] and 
White and Hu [5] demonstrated peroxidase in gels which migrated with 
a re lative mobility of around .38-thus these bands might represent 
peroxidase activity which was incapable of tyrosine hydroxylation. 
Lastly, it would have been in teresting if the S hapiro article had 
included data on analogous studies carried out on their peroxidase 
e nzyme(s), to enable one to see the electrophoretic characteristics of 
t his enzyme(s) and to assure us that its proposed tyrosine hydroxylation 
capabili ty could be determined with this same assay technique. 
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REPLY 
T he comments of Dr. Hearing are erroneous and misleading. Some 
of the points he has raised have been dealt with in previous published 
exchanges in the Journal of Investigative Dermatology. 
1. Dr. Hearing suggests that ow- inability to demonstrate hydroxyl-
ation of tyrosine by mammalian "tyrosinase" is related to the use of a 
concentration of tyrosine sufficient to produce total substrate inhibi-
tion. We are not aware of documentation of total substrate inhibition 
in any enzyme system. In a previous study [1] we used a range of 
tyrosine concentrations and found that this had no effect on the 
inabili ty of mammalian "tyrosinase" (dopa oxidase) to hydroxylate 
tyrosine. In addition, we repeated experiments in our current study, 
using a similar ra'nge of tyrosine concentration, without effect on our 
data. Conversely, hydroxyla tion of tyrosine by mushroom tyrosinase 
was easily demonstrable [2] using tyrosine concentrations equal to 
those employed wi th our mammalian "tyrosinase" experiments. 
2. Dr. Hearing's alleged inability to obtain adequate "tyrosinase" 
concent ration using our method is of no s ignificance and has no bearing 
on our results. His assay system was ambiguous, and his method of 
differentiating peroxidase from "tyrosinase" activity was withou t value 
for reasons cited previously [3]. In our previous experiments [2] and in 
the current study, our enzyme preparation (mammalian " tyrosinase" ) 
had good specific activi ty towards dopa, using non·ambiguous assay 
methods. 
3. Rx value of an enzyme will vary with many factors, including its 
polymeric form, binding to other proteins [4], and polymerization time 
used for the gel; pore size will vary with polymerization t ime. Therefore, 
Rx value cannot reliably be used as a parameter of enzyme identifica-
t ion. It is not clear why the dopa-positive bands he found at the Rx 
values cited in our current study did not represent "tyrosinase." We do 
not understand why Dr. Hearing could suggest that our dopa-positive 
bands represented hemoglobin or peroxidase, since we clearly stated 
that these bands were diaminobenzidine-negative, excluding these pos-
sibili ties. 
4. Dr. Hearing should be aware that electrophoretic characteristics 
of melanoma peroxidase cannot be determined, since this peroxidase is 
firmly membrane-bound. We made this point in our rebuttal to his 
previous paper [3]. 
The only way that the controversy about "~yrosinase" can be re-
solved is by step-by-step cross-verification of results, with exchange of 
starting materials and intermediates between laboratories with conflict-
ing data, as well as the use of non-ambiguous methods of enzyme assay. 
394 LETTERS Vol. 73, No. 5, Part I 
REFERENCES 
1. Edelstein 1M, Cariglia N, Okun MR, Patel RP, Smucker 0: Inability 
of murine melanoma melanosomal "tyrosinase" (L-dopa oxidase) 
to oxidize tyrosine to melanin in polyacrylamide gel systems. J 
Invest Dermatol 64:364-370, 1975 
3. Okun MR: Critique of Dr. Hearing's paper. J Invest Dermatol 64: 
83-84, 1975 
2. Patel RP, Okun MR, Yee WA, Wilgram GF, Edelstein LM: Inability 
of murine melanoma "tyrosinase" (dopa oxidase) to oxidize ty-
rosine in the presence or absence of dopa or dihydroxyfumarate 
cofactor. J Invest Dermatol 61:55-59, 1973 
4. Burnett J: Personal communication 
Milton R. Okun, M.D. 
Associate Professor 
Tufts University School of Medicine 
Leon M. Edelstein, M.D. 
Associate Professor 
University of California School of Medicine (Davis) 
Acknowledgment 
In order for the Society for Investigative Dermatology to generate additional funds and further expand 
its activities in the field of dermatology, a new class of membership, known as Corporate Sustaining 
M embership, has been established. The Society wishes to acknowledge the support of the following 
companies, who are Corporate Sustaining Members: 
BURROUGHS WELLCOME COMPANY 
DERMIK LABORATORIES, INC. 
HOFFMAN-LA ROCHE, INC. 
ELI LILLY AND COMPANY 
JOHNSON & JOHNSON 
NEUTROGENA CORPORATION 
OWEN LABORATORIES 
PROCTOR AND GAMBLE COMPANY 
REED & CARNRICK PHARMACEUTICALS 
SCHERING LABORATORIES 
SEARLE LABORATORIES 
STIEFEL LABORATORIES, INC. 
SQUIBB INSTITUTE FOR MEDICAL RESEARCH 
SYNTEX LABORATORIES 
TEXAS PHARMACAL COMPANY 
The Society also wishes to acknowledge Westwood Pharmaceuticals for its support of the Resident-
Fellow memberships. . 
